DURECT Corporation

10260 Bubb Rd , Cupertino, CA 95014

Public
Healthcare & Pharmaceuticals - Medical Devices
around $10 - 20M
around 100 - 250
(408) 777-1417
(408) 777-3577


Durect Corporation is a specialty pharmaceutical company focused on the development of pharmaceutical products based on its drug delivery technology platforms. The Company?s product pipeline consists of seven investigational drug candidates in clinical development, with one program the subject of a New Drug Application (NDA) with the United States Food and Drug Administration (FDA), one program in Phase III, two programs in Phase II and three programs in Phase I. The Company?s products candidates include Remoxy, POSIDUR, ELADUR, TRANSDUR-Sufentanil, ORADUR-based opioid, ORADUR-ADHD, Relday and other products. The Company's developments are focused on the application of its pharmaceutical systems technologies to products in a range of chronic and episodic disease areas, including pain, cent... (Source: SEC reports)


Competitor - 1/8
Which company is more competitive with DURECT Corporation?


36 Contacts at this company
Nancy Schulman
senior QA Specialist
Huey-Ching Su
Executive Director
Charlie Claycomb
Director, Information Technology ...
Jill H. Kawazoye Burns
Director/Senior/Exec Director ...
Huey-Ching Su
Executive Director
Susan Autio
Exe. Director Engineering Manufacturing ...
Mike Arenberg
Chief Financial Officer
Shiao-Ping Lu
Sr. Director of Biostatistics
George Brown
Sr.Director, Corporate Facilities

Oct 2, 2018 06:47:49
CUPERTINO, Calif., Oct. 1, 2018 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today the appointment of Michael H. Arenberg to the position of Chief Financial Officer, effective October 15, 2018. [...]

Oct 2, 2017 20:13:09
CUPERTINO, Calif., Oct. 2, 2017 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced a patent purchase agreement with Indivior UK Limited, an affiliate of Indivior PLC (LON: INDV), [...]

Sep 20, 2017 08:42:29
CUPERTINO, Calif., Sept. 20, 2017 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Dr. Myriam Theeuwes has joined DURECT as Senior Vice President, Clinical Development.  Dr. [...]

Sep 5, 2017 20:43:18
CUPERTINO, Calif., Sept. 5, 2017 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that management is scheduled to present at two upcoming investment conferences.  A live [...]

Aug 8, 2017 20:43:16
CUPERTINO, Calif., Aug. 8, 2017 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended June 30, 2017 and provided a corporate update. [...]

Get Started Today : Sign up in 20 seconds
Search with 20+ criteria.
Export results in seconds.
Bad emails?
No worry, we give two extras for every bad email.